Chinese biotech firm BeiGene Ltd on Thursday kicked off its initial public offering (IPO) subscription exercise on the Nasdaq-style STAR Market of the Shanghai Stock Exchange (SSE), with a target to raise about 22.2 billion yuan ($3.5 billion).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
